Fueled by high returns on its investments, the pharmaceutical industry in the United States has flourished for the past 50 years.
The regulatory strategy of demanding stringent testing then allowing market-based pricing has allowed private companies to fund ambitious research and development activities with the assurance that these investments will be recovered.
However, aggressive managed-care cost-containment strategies threaten the companies'ability to recoup research and development expenses and may affect their willingness to invest in future innovative research.
Mots-clés Pascal : Industrie pharmaceutique, Recherche développement, Brevet, Etats Unis, Amérique du Nord, Amérique, Innovation, Réglementation, Législation
Mots-clés Pascal anglais : Pharmaceutical industry, Research and development, Patents, United States, North America, America, Innovation, Regulation, Legislation
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 93-0581620
Code Inist : 002B30A08. Création : 199406.